Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Diego, CA (PRWEB) July 24, 2014 ... the reporting of molecular diagnostic test results. It ... capabilities necessary for the validation and reporting of ... oncology. Molecular diagnostics is a rapidly growing area ... infectious disease, genetic predisposition, cancer, and companion diagnostics ...
(Date:7/23/2014)... (UAE) (PRWEB) July 23, 2014 International ... recently announced that its biobanking project, Provia Laboratories ... to its growing Advisory Board. Scott Wolf , ... to have Dr. Vaught onboard with Provia’s ever-expanding Advisory ... expertise that Provia’s management team brings to this field, ...
(Date:7/23/2014)... strides in saving China,s endangered national treasure, the giant ... panda reserves that have been established and three large ... remain in the wild. , Breeding programs in ... by improving genetic diversity, avoid inbreeding and ultimately, introduce ... high-profile programs doing so far? , In a new ...
(Date:7/23/2014)... Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University of Technology ... in embedding nearly perfect semiconductor crystals into a ... hybrid nanowires, very fast and multi-functional processing units ... the future. The research results will be published ... Nano-optoelectronics are considered the cornerstone of future chip ...
Breaking Biology Technology:New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4A crystal wedding in the nanocosmos 2
... CITY, Calif. , June 17 OncoMed Pharmaceuticals, Inc. ... global strategic alliance to discover, develop and commercialize novel anti-cancer stem ... a subset of tumor cells believed to play a significant role ... , , ...
... Institute have developed a new, ultra-simple method for ... of a meter thick. The process, which requires ... surface including silicon wafers, could have important implications ... assistant professor in the Department of Physics, Applied ...
... MD ... the functional relevance of a drug treatment on the heart following direct coronary flow ... ... MD Biosciences , a Preclinical Contract Research Organization (CRO), offers in vivo models for ...
Cached Biology Technology:OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 2OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 4OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 5Researchers develop ultra-simple method for creating nanoscale gold coatings 2MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury 2
(Date:7/23/2014)... , , , , ... , , , , ... healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost entirely ...
(Date:7/23/2014)... Washington, DC -- The planet,s soil releases about 60 ... which is far more than that released by burning ... respiration. This enormous release of carbon is balanced by ... and other plant matter, as well as by the ... studies have documented that rising temperatures increase the rate ...
(Date:7/23/2014)... , July 23, 2014 BioCatch, ... detection, announced today it has been named in Gartner,s ... Market Guide replaces Gartner,s well-known Magic Quadrant for Web ... BioCatch as one of several vendors to deliver passive ... will become a standard feature of at least 30% ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Climate change and the soil 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... whole new interface between nanotechnology and neuroscience, scientists ... to detect, stimulate, and inhibit nerve signals along ... , Harvard chemist Charles M. Lieber and colleagues ... this week in the journal Science. , "We ...
... first time, researchers have developed a way to synthesize a ... it works. , Derived from a fungus discovered clinging to ... certain cancer cells into suicide while leaving healthy cells untouched. ... might have some tremendous potential as a prototype anticancer agent, ...
... Medical Research have discovered a mechanistic link between cellular ... proteins that lead to nerve cell injury and death ... , That link is Protein Disulphide Isomerase ... protein folding in times of cellular stress. Published ...
Cached Biology News:Nanowire arrays can detect signals along individual neurons 2New lab technique churns out fungus' potential cancer fighter 2Key stress protein linked to toxicities responsible for Parkinson's, Alzheimer's 2
...
... ISOQUANT(R) Isoaspartate Detection Kit is intended for ... proteins and peptides, which can result from ... rearrangement of aspartic acid residues during storage ... depend on the monitoring of charge differences ...
...
...
Biology Products: